Upstream / Downstream

Explore pathways related to this product.

Our U.S. Offices Are Closed

Our U.S. offices are closed in observance of Thanksgiving. We will reopen on Monday, December 1st.

Thank you for your patience.

To Purchase # 5452SC

5452SC 10 µg (With Carrier) $199.00
5452SF 10 µg (Carrier Free) $199.00
5452LC 50 µg (With Carrier) $599.00
5452LF 50 µg (Carrier Free) $599.00
$ 0. 00

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

Source / Purification

Recombinant humanHis6 FasL (hHis6FasL) Pro134-Leu281 (Accession #NP_000630) was expressed in human 293 cells at Cell Signaling Technology.

Product Description

Purity:

>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hHis6FasL. All lots are greater than 98% pure.


Molecular Formula:

Recombinant N-terminally His6-tagged hFasL has a calculated MW of 19,834. DTT-reduced and non-reduced protein migrate as 31-36 kDa polypeptides. Lower mobility in SDS-PAGE is due to glycosylation.


Bioactivity:

The bioactivity of hHis6FasL was determined in a Jurkat cell viability assay. The ED50 of each lot is between 1-5 ng/ml.


Endotoxin:

Less than 0.01 ng endotoxin/1 μg hHis6FasL.


Product Usage Information

Formulation:

With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg hHis6FasL. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2


Storage: Stable in lyophilized state at 4°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles.Maintain sterility. Storage at -20°C should be in a manual defrost freezer.

FasL is a member of the TNF-superfamily family of proteins and is expressed primarily on the cell surface of activated T and NK cells (1). FasL regulates the immune response through its ability to induce apoptosis. The immunoregulatory role of FasL is underscored by lymphoadenopathy associated with FasL or Fas knockout mice and the fraction of autoimmune lympho-proliferative syndrome (ALPS) patients that have mutations in the FasL receptor, Fas (1). FasL is a membrane protein that can be cleaved into a soluble trimeric form by metalloproteinases (1,2). The soluble form of FasL retains the ability to bind to Fas, however, its ability to induce apoptosis is diminished (2). The ligation of Fas by FasL leads to the assembly of death-inducing signaling complex (DISC) and the recruitment and activation of caspase-8/caspase-10 (1,3). Active caspase-8/caspase-10 subsequently activates the “effector” caspases caspase-3 and caspase-7, and cleavage of BID (1,3).


1.  Strasser, A. et al. (2009) Immunity 30, 180-92.

2.  Schneider, P. et al. (1998) J Exp Med 187, 1205-13.

3.  Guicciardi, M.E. and Gores, G.J. (2009) FASEB J 23, 1625-37.


Entrez-Gene Id 356
Swiss-Prot Acc. P48023


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.
PathScan® is a trademark of Cell Signaling Technology, Inc.